Patent · US Active

Sphingoid compounds for prophylaxis and/or therapy of a viral infection

US10688065B2 · kind B2 · utility

2Cited by

1References

3Claims

0Family size

Assignee

Harbins Ruhr Bioscience, Inc. · US

Inventors

Erich Gulbins · Heidelberg, DE
Karl Lang · Essen, DE
Judith Bezgovsek · Essen, DE

Key dates

Filing date	Sep 30, 2019
Grant date	Jun 23, 2020
Priority date	—
Expiry date	Sep 30, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y305/01109
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.